Cholangiocarcinoma (CCA) is the second most frequent primary liver neoplasia. It mainly arises from the malignant transformation of biliary epithelial cells, although it might originate from either hepatic progenitor cells at the Hering canals or transformed hepatocytes. CCA is a highly aggressive tumor with extremely poor prognosis and limited therapeutic approaches. Baicalin (BA) is one of the main bioactive flavonoids identified in the Scutellaria Baicalensis Georgi root dried extract which is extensively used in the Chinese tra-ditional medicine. Together with the anti-inflammatory effect, the anti-neoplastic action is the most relevant BA property demonstrated on cancer cells of different origin. Being aware of the need of new therapeutic weapons for CCA treatment, we in-vestigated whether Baicalin could exert anti-proliferative and anti-migratory effect on EGI-1 cells, a highly metastatic CCA cell line derived from bile duct carcinoma. We first tested different BA concentrations (from 5 to 200µM) in limiting EGI-1 via-bility using MTT assay. After 24h and 48h treatment, 5 and 10µM BA had no effect while rising from 25µM to 200µM (i.e. 25,50,100 and 200µM) BA exerted a significant cell viability reduction already at 24h and increased after 48h BA expo-sure. This reduction well correlated with the adherent absolute cell number de-crease and it cannot be due to BA induced cell cycle impairment after neither 24 nor 48h treatment. We also evaluated the anti-migratory BA potential by a wound healing assay adding different BA concentrations (5, 25, 50,100 and 200µM) to the culture medium immediately after performing a wound on confluent cell cultures. All BA concen-trations but 5µM induced a significant reduction in the EGI-1 migration rate after 24h treatment. Moreover 25, 50 and 10µM BA showed similar migration inhibition extent at 24 and 48h whilst 200µM BA exerted a stronger inhibitory effect already after 24h exposure which increased with time in a significant way. Taken together our preliminary results demonstrate that BA impairs CCA cell via-bility and migration suggesting a promising adjuvant therapeutic use for BA as an-titumoral agent.
Rigolio, R., Cadamuro, M., Caramia, G., Malacrida, A., Maggioni, D., Foudah, D., et al. (2014). Anti-proliferative and anti-migratory effects of baicalin on cholangiocarcinoma cell line egi-1. Intervento presentato a: Congresso di Istologia ed Anatomia Umana - 18 - 20 settembre, Ancona, Italy [10.13128/IJAE-16004].
Anti-proliferative and anti-migratory effects of baicalin on cholangiocarcinoma cell line egi-1
RIGOLIO, ROBERTAPrimo
;CADAMURO, MASSIMILIANOSecondo
;MALACRIDA, ALESSIO;MAGGIONI, DANIELE;FOUDAH, DANAPenultimo
;MILOSO, MARIAROSARIAUltimo
2014
Abstract
Cholangiocarcinoma (CCA) is the second most frequent primary liver neoplasia. It mainly arises from the malignant transformation of biliary epithelial cells, although it might originate from either hepatic progenitor cells at the Hering canals or transformed hepatocytes. CCA is a highly aggressive tumor with extremely poor prognosis and limited therapeutic approaches. Baicalin (BA) is one of the main bioactive flavonoids identified in the Scutellaria Baicalensis Georgi root dried extract which is extensively used in the Chinese tra-ditional medicine. Together with the anti-inflammatory effect, the anti-neoplastic action is the most relevant BA property demonstrated on cancer cells of different origin. Being aware of the need of new therapeutic weapons for CCA treatment, we in-vestigated whether Baicalin could exert anti-proliferative and anti-migratory effect on EGI-1 cells, a highly metastatic CCA cell line derived from bile duct carcinoma. We first tested different BA concentrations (from 5 to 200µM) in limiting EGI-1 via-bility using MTT assay. After 24h and 48h treatment, 5 and 10µM BA had no effect while rising from 25µM to 200µM (i.e. 25,50,100 and 200µM) BA exerted a significant cell viability reduction already at 24h and increased after 48h BA expo-sure. This reduction well correlated with the adherent absolute cell number de-crease and it cannot be due to BA induced cell cycle impairment after neither 24 nor 48h treatment. We also evaluated the anti-migratory BA potential by a wound healing assay adding different BA concentrations (5, 25, 50,100 and 200µM) to the culture medium immediately after performing a wound on confluent cell cultures. All BA concen-trations but 5µM induced a significant reduction in the EGI-1 migration rate after 24h treatment. Moreover 25, 50 and 10µM BA showed similar migration inhibition extent at 24 and 48h whilst 200µM BA exerted a stronger inhibitory effect already after 24h exposure which increased with time in a significant way. Taken together our preliminary results demonstrate that BA impairs CCA cell via-bility and migration suggesting a promising adjuvant therapeutic use for BA as an-titumoral agent.File | Dimensione | Formato | |
---|---|---|---|
2014 Rigolio Ancona Anatomia.PDF
Solo gestori archivio
Descrizione: Abstract
Dimensione
136.97 kB
Formato
Adobe PDF
|
136.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.